Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity

被引：7

作者：

Alroughani, Raed ^{[1
]}

Inshasi, Jihad ^{[2
,3
]}

Al-Asmi, Abdullah ^{[4
]}

Alqallaf, Abdulradha ^{[5
]}

Al Salti, Abdulla ^{[6
]}

Shatila, Ahmed ^{[7
]}

Boshra, Amir ^{[8
]}

Canibano, Beatriz ^{[9
]}

Deleu, Dirk ^{[9
]}

Al Sharoqi, Isa ^{[10
,11
]}

Al Khabouri, Jaber ^{[12
]}

机构：

[1] Amiri Hosp, Dept Med, Sharq, Kuwait

[2] Rashid Hosp, Dept Neurol, Dubai, U Arab Emirates

[3] DHA, Dubai Med Coll, Dubai, U Arab Emirates

[4] Sultan Qaboos Univ, Coll Med & Hlth Sci, Neurol Unit, Muscat, Oman

[5] Kuwait Univ, Div Neurol, Fac Med, Kuwait, Kuwait

[6] Khoula Hosp, Neurosci Dept, Muscat, Oman

[7] Sheikh Shakhbout Med City, Neurol Dept, Aby Dhabi, U Arab Emirates

[8] Merck Serono Middle East FZ LTD, hNeurol & Immunol Med Affairs, Patient Support Program, Dubai, U Arab Emirates

[9] Hamad Med Corp, Neurosci Inst, Dept Neurol, Doha, Qatar

[10] Salmaniya Med Complex, Dept Neurosci, Manama, Bahrain

[11] Minist Hlth, Neurol Dept, Manama, Bahrain

[12] Royal Hosp, Dept Neurol, Muscat, Oman

来源：

POSTGRADUATE MEDICINE | 2020年 / 132卷 / 04期

关键词：

Multiple sclerosis; disease-modifying therapy; consensus statement; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL TERIFLUNOMIDE; CONTROLLED PHASE-3; DIMETHYL FUMARATE; INTRAMUSCULAR INTERFERON; CLADRIBINE TABLETS; GLATIRAMER ACETATE; FINGOLIMOD; MULTICENTER;

D O I：

10.1080/00325481.2020.1734394

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent research has expanded our understanding of the natural history and clinical course of multiple sclerosis (MS) in the Arabian Gulf region. In addition, the number of available therapies for MS has increased greatly in recent years, which complicates considerably the design of therapeutic regimens. We, an expert group of physicians practising in Arabian Gulf countries, present pragmatic consensus recommendations for the use of disease-modifying therapy, according to the level of MS disease activity, according to objective criteria, and prior treatment (if any) received by a given patient.

引用

页码：368 / 376

页数：9

共 58 条

[1] Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries [J].